Aravive Inc (NASDAQ: ARAV) shares plunged after the company's Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve 
Operator: Good morning and welcome to ImmunoGen’s second quarter 2023 financial and operating results conference call. Today’s conference is being recorded.
Aravive to Participate in William Blair s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
FibroGen said on Monday its experimental drug for a chronic lung disease failed to significantly slow the decline in a key measure of lung function in a late-stage study.